MUSTARGEN (mechlorethamine hydrochloride) by Recordati is alkylating activity [moa]. Approved for alkylating drug [epc]. First approved in 1949.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
Mustargen (mechlorethamine hydrochloride) is a nitrogen mustard alkylating agent approved in 1949 for treating lymphomas and other malignancies. It works by cross-linking DNA, disrupting cell division and inducing apoptosis in rapidly dividing cancer cells. The drug is administered via injection and represents one of the earliest chemotherapy agents in clinical use.
Product is in late-stage lifecycle with modest competitive pressure (30%), indicating potential workforce transition and focus on maintaining niche market presence rather than expansion.
Alkylating Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Mustargen offers experience in lifecycle management and niche market maintenance within a stable, legacy product portfolio. Career growth is limited by LOE trajectory; roles emphasize operational excellence and physician relationship management over innovation.
Worked on MUSTARGEN at Recordati? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.